The Importance of Being Reproducible: Keith Baggerly tells the Anil Potti story

For those Retraction Watch readers who have been following the case of Anil Potti — who has now retracted four papers — Keith Baggerly’s name will likely be familiar. Baggerly is the bioinformatician at M.D. Anderson in Houston who has been publicly questioning, in letters, papers, and The Cancer Letter, work by Potti et. al.

Yesterday, Baggerly gave a keynote at the Council of Science Editors meeting in Baltimore. It was a fascinating — and riveting — walk through how, after a group at M.D. Anderson asked him and his team to evaluate the Potti group’s tools for predicting whether given patients would respond to different chemotherapies, Baggerly’s group unraveled the Potti research.

In his talk, Baggerly demonstrated all of the mislabeling and other easily recognized errors his team found when they sifted through the raw data. And yet there were a number of wince-inducing moments in which Baggerly described the cool reception he had from several journals.

There have been a lot of calls recently that journals should require that authors deposit their data.  There’s none more powerful than when they come at the end of a talk showing how that could have stopped a faulty clinical trial from ever starting.

Baggerly told Retraction Watch he just wants this story to get the widest attention possible, so he was glad to allow us to post his slides. They get appropriately technical, given the crowd, but it’s worth it. You can follow a very unofficial and rough transcript at this Twitter search, since Ivan live-tweeted the talk. Or just click over to the slideshow here.

NEJM retracts Potti paper

courtesy Duke

About a month ago, the New England Journal of Medicine told us that they didn’t “have any plans” to retract a paper by Anil Potti. Apparently, they’ve changed their minds.

Today, they posted this retraction notice: Continue reading NEJM retracts Potti paper

Two more retractions for Mori make 16 — but not a record

Biochemical Journal has retracted two articles by Naoki Mori, bringing the total number of pulled papers by the Japanese cancer researcher to sixteen.

As with the previous Mori retractions, the latest ones — of papers published in 2007 and 2010 — involve unreliable images. Mori, you’ll recall, had recycled control blots from study to study over the years, and was dismissed from his academic post in August.

The 2007 paper, “Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells,” also included a frequent co-author Mariko Tomita, who has been implicated in the deception. It has been cited 15 times, according to Thomson Scientific’s Web of Knowledge. The 2010 article, “Inhibition of Akt/GSK3β signalling pathway by Legionella pneumophila is involved in induction of T-cell apoptosis,” has not yet been cited.

In each case, the retraction notice is the same: Continue reading Two more retractions for Mori make 16 — but not a record

No Potti retractions on the horizon from JAMA, NEJM

With the third retraction of a paper by Anil Potti this weekend, plus details of various investigations dribbling out, we decided to check in with the world’s two leading medical journals about whether they planned to retract the papers of Potti’s they’d published.

JAMA published two papers by Potti and colleagues: One, “Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer,” appeared in 2008. It has been cited 51 times, according to Thomson Scientific’s Web of Knowledge, and was the subject of two letters. In one, a correspondent expressed concerns about the lack of information in the study about Continue reading No Potti retractions on the horizon from JAMA, NEJM

Lancet Oncology retracts previously questioned Anil Potti paper

courtesy Duke

Early in December, as the house of cards that is Anil Potti‘s publication record started to really collapse, we called attention to a paper in The Lancet Oncology that had already been the subject of a correction and Expression of Concern in July of last year. Today, the journal officially retracted the paper, “Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.” The paper was cited more than 100 times, according to Google Scholar.

The retraction notice: Continue reading Lancet Oncology retracts previously questioned Anil Potti paper

And that’s 14: More (and more) Mori retractions, as Japanese cancer journal pulls three papers

Naoki Mori

The steady drip-drip-dripping sound you hear from the cancer literature these days comes from the stream of retractions involving studies by Naoki Mori, the now jobless scientist whose work on cancer viruses appears to be evaporating before our eyes.

Cancer Science, which used to be called the Japanese Journal of Cancer Research,  has retracted three more of Mori’s papers, each of which, according to the journal, contained multiple unreliable images. That brings the tally of retractions involving Mori’s articles to 14 by our count, an impressive number by any measure. Mori has more than 50 papers to his name, however, so it’s possible that the number of retractions will grow.

Here are the latest retractions: Continue reading And that’s 14: More (and more) Mori retractions, as Japanese cancer journal pulls three papers

Clinical Infectious Diseases retracts antibiotic guidelines after posting uncorrected version

A few days after Clinical Infectious Diseases published a set of guidelines for using antibiotics in patients with cancer and dangerously compromised immune systems, we noticed that they had retracted the paper. The Medline notice read: Continue reading Clinical Infectious Diseases retracts antibiotic guidelines after posting uncorrected version

A lightning-fast JNCI retraction shows how science should work

The retraction last week of a commentary in the Journal of the National Cancer Institute (JNCI) looks like a nice — and very quick — example of self-correction in science.

The commentary, “Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction,” was co-authored by Stuart Baker and Daniel Sargent, and published in the December 1, 2010 issue. The journal published the retraction, and a letter that contained the re-analysis that led to it, on January 12.

The retraction notice: Continue reading A lightning-fast JNCI retraction shows how science should work

Fraud by Naoki Mori claims another paper, this one in a journal whose board he sits on

Late last month we wrote about a handful of retractions involving Naoki Mori, a promising Japanese cancer researcher who appears to have built a CV with the help of fabricated evidence.

The fraud earned Mori a 10-year publishing ban from the American Society of Microbiology, which publishes Infection and Immunity. There were two other retractions in Blood, from the American Society of Hematology.

Now, another journal has joined the party. Continue reading Fraud by Naoki Mori claims another paper, this one in a journal whose board he sits on

Update on Anil Potti: A patient in a trial based on retracted research speaks out; Baggerly on how to prevent the next fiasco

courtesy Duke

A quick post this Sunday morning to draw your attention to two must-read items for anyone interested in the Anil Potti case or in how one goes about checking data. (A second paper by Potti et al was officially retracted on Friday.)

First, a terrific profile of Joyce Shoffner in the Charlotte News & Observer. Shoffner

was one of 110 Duke patients enrolled in three clinical trials based on the research of Dr. Anil Potti, who resigned in November as an associate professor at Duke.

Here at Retraction Watch, we obviously think all retractions are worth following. But we hope this story will convince those who shrug and say such items are inside baseball, or “none of your damn business,” that they need to re-evaluate their positions. This is where the rubber hits the road: Continue reading Update on Anil Potti: A patient in a trial based on retracted research speaks out; Baggerly on how to prevent the next fiasco